Last $0.19 USD
Change Today -0.0031 / -1.64%
Volume 1.5M
NVLX On Other Exchanges
As of 5:20 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

nuvilex inc (NVLX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $0.62
52 Week Low
02/6/14 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NUVILEX INC (NVLX)

Related News

No related news articles were found.

nuvilex inc (NVLX) Related Businessweek News

No Related Businessweek News Found

nuvilex inc (NVLX) Details

Nuvilex, Inc., a biotechnology company, develops treatments for pancreatic cancer, breast cancer, brain cancer, and diabetes through cellulose-based live cell encapsulation technology. The company primarily focuses on the advancement of its treatment for advanced, inoperable pancreatic cancer that combines the Cell-in-a-Box technology with the well-known anti-cancer drug ifosfamide. It has completed two Phase 1/2 clinical trials in inoperable pancreatic cancer; and research studies in diabetes cell therapy. The company, through its subsidiary, Medical Marijuana Sciences, Inc., focuses on ways to exploit the use of live cell encapsulation technology in optimizing cancer effectiveness with cannabinoids against cancers. It also focuses on selling its names, nutraceutical formulations, and associated information technology to the third parties. The company was formerly known as, Inc. and changed its name to Nuvilex, Inc. in March 2009. Nuvilex, Inc. was founded in 1996 and is based in Silver Spring, Maryland.

4 Employees
Last Reported Date: 08/4/14
Founded in 1996

nuvilex inc (NVLX) Top Compensated Officers

Chief Executive Officer, President, General C...
Total Annual Compensation: $50.0K
Chairman of The Board and Chief Financial Off...
Total Annual Compensation: $34.0K
Chief Operating Officer and Director
Total Annual Compensation: $59.8K
Compensation as of Fiscal Year 2014.

nuvilex inc (NVLX) Key Developments

Nuvilex, Inc. Adopts Amendments to the Bylaws

Nuvilex, Inc. announced that on September 19, 2014, the Board adopted amendment no. one to the Bylaws of the company. Amendment no. one grants the Board the power to increase or decrease the number of directors on the Board from time to time and removes a limit on the number of directors on the Board.

Nuvilex, Inc. Announces Directorate Changes, Effective as of September 19, 2014

Dr. Ryan resigned from the board of directors of Nuvilex, Inc. and from his position as the Chief Scientific Officer of the company, effective as of September 19, 2014. In connection with his departure, the company entered into the Settlement Agreement pursuant to which the Company agreed to pay Dr. Ryan $183,000 in settlement of certain loans and expenses, transfer certain assets to Dr. Ryan under the terms of the Asset Purchase Agreement and allow Dr. Ryan to retain 26,036,800 shares of the Company's common stock earned and purchased. The board appointed Kenneth L. Waggoner, the company's Chief Executive Officer, President and General Counsel, to serve as a director of the company. Mr. Waggoner fills one of the vacancies created by an increase in the size of the Board from six to nine. Mr. Waggoner's term will expire at the next annual meeting of stockholders or until his successor is elected and qualified.

Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for its Cell-In-A-Box Treatment for Pancreatic Cancer

Nuvilex, Inc. announced that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. Nuvilex's pancreatic cancer treatment consists of the combination of Cell-in-a-Box(R) with low doses of the anticancer drug ifosfamide. The Cell-in-a-Box(R) portion of the treatment consists of live cells capable of converting ifosfamide into its cancer-killing form that have been enclosed in protective pin-head sized spherical capsules that are composed of bio-inert cellulose. This first submission of Nuvilex's pancreatic cancer treatment is being made in Europe because, in the mid-2000s, an application for the Orphan Drug Designation for the encapsulated live cell (Cell-in-a-Box(R)) component of the pancreatic cancer treatment was approved in principle in Europe by the precursor to the EMA - the EMEA. The sponsor of this application is Nuvilex's newest subsidiary, Nuvilex Europe Limited, which was recently formed to develop and commercialize treatments for cancer and diabetes throughout the European market. The fact that 82,000 deaths from pancreatic cancer are predicted in the European Union in 2014, that it is incurable in more than 95% of patients and that median survival is much less than one year all testify to the life-threatening nature of the disease. Importantly, as noted above, the Orphan Drug Designation in Europe for a drug or treatment carries with it an extension of 10 years of marketing exclusivity after marketing approval is granted by the EMA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVLX:US $0.19 USD -0.0031

NVLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.06 USD +0.0008
GW Pharmaceuticals PLC 435.75 GBp -4.50
Medical Marijuana Inc $0.11 USD -0.0055
View Industry Companies

Industry Analysis


Industry Average

Valuation NVLX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVILEX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at